A safe approach to treatment of factor IX-deficient patients. Introduction and overview of treatment.
作者信息
Aledort L M
机构信息
Mt. Sinai Medical Center, New York, NY 10029.
出版信息
Semin Hematol. 1991 Jul;28(3 Suppl 6):1-2.
PMID:1780765
Abstract
摘要
相似文献
1
A safe approach to treatment of factor IX-deficient patients. Introduction and overview of treatment.
Semin Hematol. 1991 Jul;28(3 Suppl 6):1-2.
2
Recombinant factor IX for the treatment of hemophilia B. Introduction.用于治疗B型血友病的重组凝血因子IX。引言。
Semin Hematol. 1998 Apr;35(2 Suppl 2):1-3.
3
Viral safety of recombinant factor IX.重组凝血因子IX的病毒安全性
Semin Hematol. 1998 Apr;35(2 Suppl 2):22-7.
4
Considerations governing factor IX product choice in hemophilia B.B型血友病中IX因子产品选择的相关考量因素
Transfusion. 1994 Jun;34(6):554-5. doi: 10.1046/j.1537-2995.1994.34694295077.x.
5
Current management of hemophilia B.目前B型血友病的治疗方法。
Hematol Oncol Clin North Am. 1993 Dec;7(6):1269-80.
6
[Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].[病毒灭活的凝血因子VIII和IX浓缩物在血友病治疗中的病毒安全性现状]
Infusionsther Transfusionsmed. 1994 Aug;21 Suppl 1:80-3.
7
Thrombogenicity associated with factor IX complex concentrates.与凝血因子IX复合物浓缩物相关的血栓形成性。
Semin Hematol. 1991 Jul;28(3 Suppl 6):3-5.
8
[Use of 2 preparations of factor IX concentrate in the treatment of a patient with hemophilia B].
Ned Tijdschr Geneeskd. 1972 Jul 22;116(30):1278-82.
9
Preclinical studies of recombinant factor IX.重组因子IX的临床前研究。
Semin Hematol. 1998 Apr;35(2 Suppl 2):28-32.
10
Recombinant factor IX.重组凝血因子IX
Thromb Haemost. 1997 Jul;78(1):261-5.
Zotero 插件